Obesity diminishes response to PD-1-based immunotherapies in renal cancer

BACKGROUND: Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and...

Descripción completa

Detalles Bibliográficos
Autores principales: Boi, Shannon K, Orlandella, Rachael M, Gibson, Justin Tyler, Turbitt, William James, Wald, Gal, Thomas, Lewis, Buchta Rosean, Claire, Norris, Katlyn E, Bing, Megan, Bertrand, Laura, Gross, Brett P, Makkouk, Amani, Starenki, Dmytro, Farag, Kristine I, Sorge, Robert E, Brown, James A, Gordetsky, Jennifer, Yasin, Hesham, Garje, Rohan, Nandagopal, Lakshminarayanan, Weiner, George J, Lubaroff, David M, Arend, Rebecca C, Li, Peng, Zakharia, Yousef, Yang, Eddy, Salem, Aliasger K, Nepple, Kenneth, Marquez-Lago, Tatiana T, Norian, Lyse A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757487/
https://www.ncbi.nlm.nih.gov/pubmed/33427691
http://dx.doi.org/10.1136/jitc-2020-000725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757487/
https://www.ncbi.nlm.nih.gov/pubmed/33427691
http://dx.doi.org/10.1136/jitc-2020-000725

Ejemplares similares